Thermo Fisher Scientific Launches Efficient-Pro Medium (+) Insulin  

Thermo Fisher Scientific launched the Gibco Efficient-Pro Medium (+) Insulin, a next-generation medium designed to increase titers to maximize productivity and performance of insulin-dependent CHO cell lines. 

Designed for biopharma manufacturers and CDMOs focused on CHO-based therapeutics, efficient-Pro Medium (+) Insulin is designed to offer improved protein yield and optimized productivity for insulin-dependent CHO cell lines commonly used in monoclonal antibody and biosimilar production, as well as simplify the preparation process and logistics. 

According to the company, the solution offers up to 61% higher protein titers compared to other alternatives; High viable cell densities and robust growth without compromising product quality; Compatibility with a broad range of insulin-dependent CHO cell lines; Dry format compatibility for rapid reconstitution and scalability;  and animal origin–free (AOF) formulation to reduce process variability and ease regulatory complexity.

“Our announcement represents a significant enhancement in bioprocessing technology,” said Sara Henneman, vice president and general manager of Thermo Fisher Scientific’s cell culture and cell therapy business. “By integrating our AGT format and ensuring an AOF formulation, we are addressing key industry challenges and providing our customers with a reliable, high-performance solution. Efficient-Pro Medium (+) Insulin underscores our dedication to innovation and our mission to support the development of groundbreaking therapies that improve patient outcomes worldwide.”